Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials

• Main Authors: Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, Teresa Gamucci, Clara Natoli, Antonino Grassadonia, Nicola Tinari, Silverio Tomao, Isabella Sperduti, Giuseppe Sanguineti, Andrea Botticelli, Agnese Fabbri, Claudio Botti, Gennaro Ciliberto, Maddalena Barba, Patrizia Vici
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Cancers
• Subjects: triple-negative breast cancer; immune check point inhibitor; neoadjuvant therapy; meta-analysis
• Online Access: https://www.mdpi.com/2072-6694/12/9/2497

Chemotherapy based on the sequential use of anthracyclines and taxanes has long represented the most efficacious approach in the management of early-stage, triple-negative breast cancer, whose aggressive behavior is widely renowned. This standard chemotherapy backbone was subsequently enriched by the use of carboplatin, based on its association with increased pathologic complete response and efficacy in the metastatic setting. Following the results from the IMpassion130 trial, the recent approval of the immunotherapic agent atezolizumab in combination with chemotherapy as first-line treatment for programmed-death ligand 1-positive, unresectable locally advanced, or metastatic triple-negative breast cancer increasingly fueled the flourishing of trials of immune-checkpoint inhibitors in the early setting. In this work, we review the most recent inherent literature in light of key methodological issues and provide a quantitative summary of the results from phase II–III randomized trials of immunotherapic agents combined with chemotherapy in the setting of interest. Hints regarding future directions are also discussed.